Grade: F — Major Red Flags (REIT-Structural + Net Loss)
Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles
Data: SEC EDGAR 10-K (Filed 2026-01-26, FY ended December 31, 2025) + Yahoo Finance
Auditor: Ernst & Young LLP — Unqualified opinion
CIK: 0001035443
One-line verdict: Alexandria is the most concerning REIT in this batch. The company reported a net loss of $1.4B in FY2025, driven by impairments and mark-to-market losses on its venture capital portfolio. Revenue declined 3.4% to $2.9B. CFFO/NI of -0.99 is negative because NI itself is negative — but operating cash flow of approximately $1.4B remains positive. Debt/EBITDA of 35.4x is alarming on its face, but this is distorted by the net loss dragging down EBITDA. Cash of $529M covers only 4% of $12.8B in debt. The one saving grace: zero goodwill on the balance sheet, and the M-Score of -2.82 shows no manipulation. This is a life science REIT under genuine stress, not cooking books — but the financial position demands close scrutiny.
| Metric | Result |
|---|---|
| Red Flags | **1** (Cash-to-debt 4%) |
| Watch Items | **2** (CFFO/NI negative, Debt/EBITDA 35.4x) |
| Checks Completed | **16/18** (2 N/A) |
| Beneish M-Score | **-2.82** (clean) |
| Auditor | Ernst & Young LLP — Unqualified opinion |
The Life Science REIT Under Pressure
Alexandria is the dominant life science and AgTech-focused REIT, with properties concentrated in Cambridge, San Francisco, San Diego, Seattle, and other innovation clusters. Per the filing, "our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy rates."
Revenue declined 3.4% to $2.9B reflecting tenant losses in the life science sector, where biotech funding cycles directly impact space demand. The net loss of $1.4B was primarily driven by non-cash items — impairments on development projects, mark-to-market losses on the venture capital portfolio, and depreciation.
Key REIT metrics from the filing: NOI and FFO provide a more accurate picture than GAAP net income for this REIT. The filing defines NOI excluding "the impact of straight-line rent, above- and below-market leases and tenant-funded improvements." The filing states that "net operating income is useful to investors as a performance measure of our consolidated properties because, when compared across periods, net operating income reflects trends in occupancy rates, rental rates, and operating costs."
Debt and Liquidity
Cash of $529M against $12.8B in total debt is a thin cushion. For a REIT with a net loss and revenue declines, the ability to refinance is paramount. The filing's risk factors extensively discuss the risk that "actual or anticipated changes in rental rates, leasing activity, occupancy levels, or real estate valuations" and "the amount and timing of debt maturities" could affect access to capital markets.
The filing notes FFO per share guidance changes and warns that "actual or anticipated variations in our quarterly or annual operating results, dividends, net income, funds from operations, or guidance" could affect the stock price.
The 18-Point Screening
| # | Check | Result | Detail |
|---|---|---|---|
| A1 | DSO Change | ✅ | DSO 1 day, stable |
| A2 | AR vs Revenue Growth | ✅ | AR +4.1% vs revenue -3.4% |
| A3 | Revenue vs CFFO | ✅ | Both declining proportionally |
| B1-B4 | Expense Checks | ✅ | SG&A/Gross Profit 5.8% (excellent), 68.7% gross margin |
| C1 | CFFO vs Net Income | ⚠️ | Ratio -0.99 (NI is negative) |
| C2 | Free Cash Flow | ✅ | FCF $1.4B positive |
| C3 | Accruals Ratio | ✅ | -8.3%, very low |
| C4 | Cash vs Debt | ❌ | Cash $529M = 4% of $12.8B debt |
| D1 | Goodwill | ✅ | Zero goodwill |
| D2 | Leverage | ⚠️ | Debt/EBITDA 35.4x (distorted by loss) |
| D3-D4 | Soft Assets/Impairment | ✅ | Normal |
| E1-E2 | Acquisition Risk | ✅ | Clean |
| F1 | Beneish M-Score | ✅ | -2.82 (clean) |
Key Risks
Life science tenant demand. Biotech funding is cyclical. If venture capital and IPO markets remain tight, tenant demand for lab space contracts.
Development pipeline risk. Alexandria has a significant development pipeline; any delays or cost overruns further stress a balance sheet already carrying $12.8B in debt.
Leverage. At 35.4x Debt/EBITDA (loss-distorted), any ratings downgrade would materially increase borrowing costs.
Summary
Grade: F reflects genuine financial stress, not just REIT structure. Unlike most REITs in this batch where the F grade is structural, Alexandria's negative net income, revenue decline, and extreme leverage ratio warrant real caution. The M-Score is clean and the balance sheet has zero goodwill, but the combination of $12.8B in debt, a $1.4B net loss, and a life science sector in cyclical downturn makes this a company to monitor closely.
**Disclaimer**: This report is based on Alexandria Real Estate's FY2025 10-K filed with SEC EDGAR on January 26, 2026. This is NOT investment advice.
Data: SEC EDGAR 10-K + Yahoo Finance
Auditor: Ernst & Young LLP (Unqualified opinion)
Fiscal year ended: December 31, 2025